Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Metabolic Factors of Outcomes From Gastric Bypass Surgery (Cassini)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01347840
Recruitment Status : Terminated (Study was terminated for business reasons.)
First Posted : May 4, 2011
Results First Posted : May 21, 2012
Last Update Posted : May 21, 2012
Sponsor:
Information provided by (Responsible Party):
Ethicon Endo-Surgery

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The objective of this study is to determine whether the metabolic, endocrine and energetic response to short term caloric restriction are factors in weight loss in subjects having gastric bypass (GB) surgery.

Condition or disease
Obesity

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 1 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Metabolic Factors of Outcomes From Gastric Bypass Surgery
Study Start Date : April 2011
Actual Primary Completion Date : March 2012
Actual Study Completion Date : March 2012
Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
All Subjects
This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percent Excess Weight Loss [ Time Frame: 16 months ]
    Calculated as the difference between the baseline weight and weight at endpoint divided by the difference between baseline weight and ideal body weight using the medium frame range in the Metropolitan Tables for Life Insurance, 1983 x 100.

  2. Resting Energy Expenditure [ Time Frame: 16 months ]
    Energy expended at rest (minimal movement) and during fasting. Resting Energy Expenditure can be expressed per minute or per hour or per day.

  3. Area Under the Curve of Ghrelin and GLP-1 [ Time Frame: 16 months ]
    These variables will measure the combined effects of hormone concentration and duration.


Secondary Outcome Measures :
  1. Area Under the Curve of Timed Gastrointestinal Hormones (Insulin, GIP, Pancreatic Polypeptide, Peptide YY (PYY), Amylin, Glucagon, Pro-Insulin, C-Peptide) [ Time Frame: 16 months ]
    These variables will measure the combined effects of hormone concentration and duration.

  2. Adiponectin and Lectin [ Time Frame: 16 months ]
    These laboratory values will be collected at Visit 3, Visit 5, Visit 6, and Visit 10.

  3. Subject Questionnaires [ Time Frame: 16 months ]
    The subscales and total scores as set out in the scoring algorithms for Food Craving Inventory-II and Questionnaire on Craving for Sweet and Rich Foods will be presented.

  4. Area Under the Curve of Glucose [ Time Frame: 16 months ]
    This variable will measure the combined effects of glucose concentration and duration.

  5. Hemoglobin A1c and Lipid Panel [ Time Frame: 16 months ]
    These laboratory values will be collected at Screening, Visit 8, and Visit 10.

  6. Body Mass Index [ Time Frame: 16 Months ]
    Will be calculated at Screening, Visit 3, Visit 5, Visit 6, Visit 8, and Visit 10.

  7. Percent Weight Loss [ Time Frame: 16 Months ]
    (Weight at Baseline - Weight at Each Visit) divided by the (Weight at Baseline).


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects having gastric bypass (GB) surgery within 4 months of screening visit.
Criteria

Inclusion Criteria:

Subjects satisfying the following criteria will be considered the screening population and will be eligible for enrollment in this study:

  1. Subject is willing to give consent and comply with evaluation and treatment schedule
  2. 18 to 65 years of age (inclusive) on date of signing the ICD
  3. Subject is scheduled to have non-revisional GB surgery between 2 weeks to 4 months after signing the ICD
  4. Able to read, understand, and follow study procedures as outlined in the ICD.

Exclusion Criteria:

Subjects meeting the following criteria will not be eligible for enrollment:

  1. Unable or unwilling to attend follow-up visits and examinations
  2. Women who are pregnant, nursing at the time of screening, or planning to become pregnant within one year of the GB surgery
  3. Clinically active cardiac, renal, hepatic or GI disorders

  4. Screening laboratory tests with any of the following:

    • alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST] ≥ 4 times upper limit of normal (ULN) according to VAMC normal ranges
    • AST:ALT > 2:1 according to VAMC normal ranges
    • Serum Creatinine ≥ 1.5 times ULN according to VAMC normal ranges
    • Blood Urea Nitrogen (BUN) ≥ 1.5 times ULN according to VAMC normal ranges
    • Positive test results for Hepatitis A, B or C

  5. Clinically active thyroid or lipid disorders:

    • Thyroid-stimulating hormone (TSH) flagged as critical value (per VAMC lab normal ranges)
    • Triglycerides > 400 mg/dL

  6. Anemia:

    • Mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) outside normal VAMC range; or
    • Hematocrit < 36%
  7. Uncontrolled hypertension which required a medication regimen adjustment during the 3 months prior to screening
  8. Currently prescribed or taking atypical antipsychotic medication
  9. Currently prescribed or taking chronic, long-term, oral corticosteroid medication
  10. Diabetes requiring a drug regimen which includes insulin treatment at the time of screening
  11. Unwilling or unable to refrain from having a procedure or surgery which involves the removal of skin tissue which could result in weight loss
  12. Any medical condition or finding for which the PI used medical discretion to determine the subject should be excluded; or
  13. Participation in any other investigational device or drug study (non survey based trial) during the course of the trial.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01347840


Locations
Layout table for location information
United States, Ohio
Veterans Affairs Medical Center
Cincinnati, Ohio, United States, 45267
Sponsors and Collaborators
Ethicon Endo-Surgery
Investigators
Layout table for investigator information
Principal Investigator: David D'Alessio, MD Veterans Affairs Medical Center, Cincinnati, OH
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Ethicon Endo-Surgery
ClinicalTrials.gov Identifier: NCT01347840    
Other Study ID Numbers: CI-10-0004
First Posted: May 4, 2011    Key Record Dates
Results First Posted: May 21, 2012
Last Update Posted: May 21, 2012
Last Verified: April 2012
Keywords provided by Ethicon Endo-Surgery:
Obesity Gastric Bypass Roux en Y
Additional relevant MeSH terms:
Layout table for MeSH terms
Obesity
Overnutrition
Nutrition Disorders
Overweight
Body Weight